Health knowledge made personal
Join this community!
› Share page:
Search posts:

Biomarkers for Niemann-Pick Disease Type C and Related Disorders of Oxysterol Accumulation

Posted Feb 21 2012 7:00pm

Description of Invention:
Niemann-Pick disease type C (NPC) is a lethal lysosomal storage disorder characterized by liver disease and progressive neurodegeneration. Lysosomal storage is impaired by oxidized cholesterol (oxysterol) accumulation. Presenting signs and symptoms are nonspecific, and the diagnosis is frequently difficult and delayed. The inventors established a rapid ELISA assay to evaluate biomarker levels in serum. The ELISA assay tests a novel combination of two biomarkers significantly elevated in NPC patients, Cathepsin D and Galectin-3. Other diseases can cause oxysterol accumulation, including other lysosomal storage diseases, cholesterol trafficking diseases, and neurodegenerative diseases. At least for the lysosomal storage diseases, the combination of elevated Cathepsin D and Galectin-3 appears specific for NPC. Cathepsin D is a lysosomal enzyme involved in protein degradation. The secreted Galectin-3 is mostly known as a chemoattractant for immune cells.

  • NPC diagnosis
  • NPC patient disease progression monitoring
  • NPC therapeutic efficacy testing in Clinical Trials
  • Application of above methods to related diseases

  • Fast and non-invasive ELISA serum assay
  • Potential for high sensitivity
  • Cost effective

Development Status:
  • Pilot
  • Early-stage
  • In vivo data available (animal)
  • In vivo data available (human)

Forbes D Porter (NICHD)

Patent Status:
HHS, Reference No. E-302-2011/0
US, Application No. 61/576,062 filed 15 Dec 2011

For Licensing Information Please Contact:
Betty Tong Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-594-6565
Fax: 301-402-0220

Ref No: 2371

Updated: 02/2012

Post a comment
Write a comment:

Related Searches